EDITORIALTrick or TREAT? More Safety Data of Infliximab During PregnancyKane, Sunanda MD, MSPH Author Information Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. Correspondence: S.K. (email: [email protected]) Received 30 July 2018; accepted 11 September 2018; Published online 17 October 2018 American Journal of Gastroenterology: November 2018 - Volume 113 - Issue 11 - p 1592-1593 doi: 10.1038/s41395-018-0372-5 Buy Metrics Abstract Infliximab was the first FDA approved biologic for the treatment of Crohn's disease. Data for its use before and during pregnancy in both females and males have been increasing over the last decade, but most studies have had fewer than 100 patients and inconsistent comparison to healthy control outcomes. New data from the TREAT Safety Registry have a robust N of female and male patients exposed to infliximab with known birth outcomes from both academic and community settings. There does not appear to be any increase in adverse pregnancy outcomes from this population. © The American College of Gastroenterology 2018. All Rights Reserved.